Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eisai to collaborate with Prism BioLab on new cancer drug

Eisai to collaborate with Prism BioLab on new cancer drug

5th April 2011

Eisai is entering into collaboration with Prism BioLab to develop a potentially promising new CBP/beta-catenin inhibitor compound as a cancer therapy.

The agreement will see Eisai gain exclusive global commercialisation rights to the new drug, which was discovered by Prism and is intended for use as a treatment for solid tumours and leukaemia.

It will also give Eisai an option to acquire rights to any compounds that are analogous to the treatment, as well as permitting the company to sublicense the drug.

Prism has already commenced phase Ia/Ib clinical trials of the compound, the development of which is representative of the growing role played by protein research in cancer drug development.

A company statement said: "Eisai defines oncology as a therapeutic area of focus and is committed to the development of novel anticancer agents and treatments for supportive care."

This comes after the firm received approval last month to launch Halaven, its new treatment for breast cancer, in the UK and Europe.ADNFCR-8000103-ID-800487330-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.